Streetbeat News

ENLV

Enlivex Therapeutics Ltd.

https://www.enlivex.com

Industry

Biotechnology

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

Open

1.25

Mkt cap

26M

Volume

92K

High

1.29

P/E Ratio

-1.05

52-wk high

4.59

Low

1.21

Div yield

N/A

52-wk low

1.15

Enlivex has received a Notice of Allowance for its Japanese patent application for the use of Allocetra in treating osteoarthritis. The patent is expected to be formally issued in Japan by the end of Q2 2025.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 12:07 pm

HC Wainwright & Co. has reiterated its Buy rating for Enlivex Therapeutics, maintaining a price target of $6. Analyst Raghuram Selvaraju continues to support the stock, indicating confidence in its potential.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 10:45 am

EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Enlivex Therapeutics (NASDAQ:ENLV) and maintained a price target of $13.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 6:38 pm

Enlivex has received approval from the Danish Medicines Agency to commence Phase II trials of Allocetra for moderate to severe knee osteoarthritis, following a positive safety review.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:44 pm

EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Enlivex Therapeutics (NASDAQ:ENLV) and maintained a price target of $13.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 2:13 pm

Enlivex has received a recommendation from the Data and Safety Monitoring Board (DSMB) to proceed with the Phase II stage of its Allocetra trial for moderate to severe knee osteoarthritis, following a successful Phase I safety review.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:37 pm

HC Wainwright & Co. has reiterated its Buy rating for Enlivex Therapeutics, maintaining a price target of $6. Analyst Raghuram Selvaraju continues to support the stock, indicating confidence in its potential.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 10:22 am

EF Hutton has initiated coverage on Enlivex Therapeutics with a Buy rating and set a price target of $13.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 12:07 pm

Enlivex has received authorization from the Israeli Ministry of Health to initiate a Phase I clinical trial for Allocetra in patients with psoriatic arthritis.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:08 pm

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) has dosed the first patient in a Phase I/II trial for AllocetraTM, targeting thumb osteoarthritis. This trial aims to evaluate the safety and efficacy of AllocetraTM in up to 46 patients, with no current FDA-approved therapies for this condition.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.